Med Business World

Your source for healthcare business

Ragnhild Berg

Beyeonics Surgical Announces the First Use of the Beyeonics Maverick System in Surgery

The Beyeonics™ Maverick system has been used in surgery for the first time to successfully give surgeons enhanced visual and operational capabilities during neurosurgical and orthopedic procedures. The headset-based interface uses a state-of-the-art augmented reality visualization system originally developed for F-35…

TOP PMR SPECIALIST DR. AASTIK BHATT JOINS HCAH

HCAH, India’s leading full-stack rehab and geriatric platform today announced a significant development by welcoming Dr Aastik Bhatt, a renowned physiatrist (commonly referred to as a PMR specialist – Physical Medicine and Rehabilitation), to its growing team. Dr Bhatt’s arrival…

PLUSS Advanced Technologies launches Brrf PLUSS Jackets

Pluss Advanced Technologies has launched a cooling wearable technology that can be worn by workers who are outdoors, such as on construction sites, mines, furnaces, shopfloor, in order to prevent heat stress related injuries and fatigue during hot temperatures. A…

MigraKet® Brings the World’s First Medical Food For Migraine to the U.S

International wellness brand Brain Ritual is launching MigraKet®, a revolutionary approach to migraine management developed by renowned neuroscientist and former chronic migraineur, Elena Gross, PhD. With the U.S. release of MigraKet®, sufferers of migraine can anticipate a newfound hope in managing their condition…

AITRICS to Participate in HIMSS USA 2024

AITRICS (CEO Kwang joon Kim), a company specializing in medical artificial intelligence (AI) technology announced on the 11th that it would participate in the ‘HIMSS Global Health Conference & Exhibition’ (2024 HIMSS USA) held in Orlando, Florida, USA from March 11 to 15….

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA)…

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced the publication of a peer-reviewed article titled, “A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity” in…

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company’s on-body injector (OBI) presentation of UDENYCA® (pegfilgrastim-cbqv), is successfully underway, with a broad distribution of accounts nationwide ordering this innovative device, and patients now accessing its benefits….

Dragonfly Announces Clinical Collaboration Exploring Combinations Between Dragonfly’s DF1001 HER-2 TriNKET® and Gilead’s Trodelvy® in Two Cancer Indications

Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune activating device developed using Dragonfly’s TriNKET technology platform and Dragonfly’s lead clinical asset, with Trodelvy,…

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA)…